NCT02055547 - A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2013

Primary Completion Date

September 17, 2013

Study Completion Date

September 17, 2013

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

MK-8521 35μg

Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)

DRUG

MK-8521 100μg

Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)

DRUG

MK-8521 125μg

Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

DRUG

MK-8521 150μg

Single dose 150μg SC injection in a treatment period (Part 1, Panel B)

DRUG

MK-8521 175μg

Single dose 175μg SC injection in a treatment period (Part 1, Panel B)

DRUG

MK-8521 200μg

Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)

DRUG

MK-8521 300μg

Single dose 300μg SC injection in a treatment period (Part 1, Panel A)

DRUG

MK-8521 50/72μg

MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)

DRUG

MK-8521 72/125μg

MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)

DRUG

MK-8521 100/150μg

MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)

DRUG

MK-8521 125/150μg

MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)

DRUG

Placebo

Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY